- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01305291
Fibersol-2 Clinical Trials Related to Appetite
February 25, 2011 updated by: Iowa State University
Emerging research suggests fiber, particularly digestion-resistant maltodextrins such as Fibersol-2, may impact satiety, by decreasing hunger, prolonging satiation, and/or increasing satiety signals from the gut.
This research aims to determine whether or not Fibersol-2 may impact satiety, by decreasing hunger, prolonging satiation, and/or increasing satiety signals from the gut.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Iowa
-
Ames, Iowa, United States, 50011
- Nutrition and Wellness Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 62 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
i. No known food allergies
ii. Normal healthy individuals
iii. No food intake abnormalities or abnormal feeding behaviors
iv. Average American BMI (21-28)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: tea only without fibersol-2
|
|
Active Comparator: tea only with fibersol-2 (10 g)
|
Other Names:
|
Placebo Comparator: tea without fibersol-2 and meal
|
|
Experimental: tea with 5 g fibersol-2 and meal
|
Other Names:
|
Experimental: tea with 10 g fibersol-2 and meal
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual analog scale questionnaire subjective satiety responses
Time Frame: 4 hours
|
Hunger survey (30 minutes before meal and every half hour for 4 hours postprandial) (analogue scores)
|
4 hours
|
serum cholecystokinin (CCK)
Time Frame: 4 hours
|
0, 30, 60, 120, 180, and 240 min post-meal
|
4 hours
|
serum peptide YY (PYY)
Time Frame: 4 hours
|
0, 30, 60, 120, 180, and 240 min post-meal
|
4 hours
|
serum glucagon-like peptide-1 (GLP-1)
Time Frame: 4 hours
|
0, 30, 60, 120, 180, and 240 min post-meal
|
4 hours
|
serum ghrelin
Time Frame: 4 hours
|
0, 30, 60, 120, 180, and 240 min post-meal
|
4 hours
|
serum gastric inhibitory peptide (GIP)
Time Frame: 4 hours
|
0, 30, 60, 120, 180, and 240 min post-meal
|
4 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
serum total cholesterol
Time Frame: 4 hours
|
0, 30, 60, 120, 180, 240 min
|
4 hours
|
serum LDL-cholesterol
Time Frame: 4 hours
|
0, 30, 60, 120, 180, 240 min
|
4 hours
|
serum HDL-cholesterol
Time Frame: 4 hours
|
0, 30, 60, 120, 180, 240 min
|
4 hours
|
serum triglycerides
Time Frame: 4 hours
|
0, 30, 60, 120, 180, 240 min
|
4 hours
|
serum free fatty acids
Time Frame: 4 hours
|
0, 30, 60, 120, 180, 240 min
|
4 hours
|
serum glucose
Time Frame: 2 hours
|
0, 30, 60, 90, 120 min
|
2 hours
|
serum insulin
Time Frame: 2 hours
|
0, 30, 60, 90, 120 min
|
2 hours
|
gastrointestinal symptoms questionnaire
Time Frame: 24 h
|
subjects recorded incidents and severity of gastrointestinal symptoms post treatment over 24 h
|
24 h
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Suzanne Hendrich, PhD, Iowa State University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2008
Primary Completion (Actual)
July 1, 2009
Study Completion (Actual)
November 1, 2009
Study Registration Dates
First Submitted
February 25, 2011
First Submitted That Met QC Criteria
February 25, 2011
First Posted (Estimate)
February 28, 2011
Study Record Updates
Last Update Posted (Estimate)
February 28, 2011
Last Update Submitted That Met QC Criteria
February 25, 2011
Last Verified
February 1, 2011
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ADM FB2-1 Hendrich
- 08-291 (Other Identifier: ISU IRB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lack of Satiety
-
University of GuelphCompleted
-
University of LeedsAlmond Board of CaliforniaCompletedHyperphagia | Lack of Satiety
-
Skane University HospitalCompleted
-
Solae, LLCGlycemic Index Laboratories, IncCompleted
-
University of GuelphUniversity of Toronto; Laval UniversityCompletedHyperglycemia | Lack of SatietyCanada
-
University of GuelphBunge Global Innovation IncorporatedCompletedHyperglycemia | Lack of SatietyCanada
-
University of California, DavisCompletedAppetite Disorders | Lack of Satiety | Excess Intake of MacronutrientsUnited States
-
The University of Texas at ArlingtonUniversity of South Florida; Center for Transportation, Equity, Decisions and...CompletedLack of Resources | Lack of MobilityUnited States
-
Ospedale San DonatoSoremartec Italia S.r.l.CompletedAttention Deficit and Disruptive Behavior Disorders | Lack of Satiety | Feeding BehaviorsItaly
-
Purdue UniversityCompletedObesity | Dietary Modification | Lack of Satiety | Memory DeficitsUnited States
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States